Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol

Authors

Abdullah Abou-Samra, Retina Group of Washington, Reston, VA, USA.
Muhi Dean Barazi, Retina Group of Washington, Reston, VA, USA.
Amira Abbas, Department of Ophthalmology, Georgetown University School of Medicine, Washington, DC, USA.
Omar Sabbagh, West Virginia University, Morgantown, WV, USA.
Yusuf Bade, School of Medicine, George Washington University, Washington, DC, USA.
Brian K. Do, Retina Group of Washington, Reston, VA, USA.
Jeanette Du, Retina Group of Washington, Reston, VA, USA.
Jared Ebert, Retina Group of Washington, Reston, VA, USA.
Jordana Fein, Retina Group of Washington, Reston, VA, USA.
Joshua D. Levinson, Retina Group of Washington, Reston, VA, USA.
Alexander Melamud, Retina Group of Washington, Reston, VA, USA.
Osama Sabbagh, Retina Group of Washington, Reston, VA, USA.
Mohsin H. Ali, Retina Group of Washington, Reston, VA, USA.

Document Type

Journal Article

Publication Date

9-3-2025

Journal

Journal of vitreoretinal diseases

DOI

10.1177/24741264251367100

Keywords

age-related macular degeneration; avacincaptad pegol; complement inhibition; geographic atrophy; intraocular inflammation; safety; vasculitis

Abstract

To present the first real-world safety data describing the clinical experience of geographic atrophy (GA) treatment with avacincaptad pegol in a large cohort. A retrospective, observational cohort study was conducted within the PRISM Vision Group by filtering for J codes for avacincaptad pegol from August 3, 2023, to October 10, 2024. The study included 461 eyes of 335 patients with GA who were treated with intravitreal avacincaptad pegol 2 mg (0.1 mL of 20 mg/mL) injections. The mean follow-up time was 120 days. The mean injection interval was 52 days. Fourteen eyes (3%) developed an acute rise in intraocular pressure, and there were no reports of endophthalmitis, intraocular inflammation, or nonarteritic anterior ischemic optic neuropathy. Eight eyes (2.03%) converted to neovascular age-related macular degeneration, with an average of 2 injections before conversion and a predicted annualized rate of conversion of approximately 6.17%. One eye (0.2%) developed a vitreous hemorrhage. This study describes the real-world safety profile of avacincaptad pegol that may aid clinicians in understanding the risk of adverse events associated with this relatively new treatment for GA.

APA Citation

Abou-Samra, Abdullah; Barazi, Muhi Dean; Abbas, Amira; Sabbagh, Omar; Bade, Yusuf; Do, Brian K.; Du, Jeanette; Ebert, Jared; Fein, Jordana; Levinson, Joshua D.; Melamud, Alexander; Sabbagh, Osama; and Ali, Mohsin H., "Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol" (2025). GW Authored Works. Paper 8002.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8002

Department

School of Medicine and Health Sciences Student Works